创新药概念再度活跃，三生国健20%涨停，亚太药业3连板

Group 1 - The innovative drug concept is experiencing renewed activity, with notable stock performances including Sangfor's 20% limit up and multiple companies like Asia-Pacific Pharmaceutical and Guizhou BaiLing also hitting limit up [1] - The pharmaceutical and biotechnology sector has been underperforming recently, lagging behind major market indices [1] - Novo Nordisk's acquisition of Akero highlights a trend where multinational corporations in Europe and the US are enriching their R&D pipelines through mergers and acquisitions [1] Group 2 - The European Society for Medical Oncology (ESMO) will hold its conference from October 17 to 21 in Berlin, where new research abstracts will be presented, creating anticipation for data from domestic innovative drugs and new business development opportunities [1] - Domestic innovative drug companies are rapidly gaining global competitiveness, and the innovative drug sector is expected to remain a key investment theme in the medium to long term [1] - The innovative drug sector is projected to continue showing high revenue growth and reducing losses, with expectations for the third quarter to maintain this trend [1] Group 3 - Investment opportunities are suggested in segments with improving performance, such as CXO, upstream scientific reagents, and medical devices [1]